Drugs / YL201
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06898957 | May 2025 → Jun 2031 expected | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06394414 | Apr 2024 → Apr 2027 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07407933 | Mar 2026 → Nov 2028 expected | small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07258979 | Nov 2025 → Feb 2028 expected | nasopharyngeal carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07208773 | Oct 2025 → Jan 2027 expected | non-small cell lung carcinoma, small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06057922 | Sep 2023 → Oct 2026 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05434234 | May 2022 → Apr 2027 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06241846 | Feb 2024 → Feb 2027 expected | prostate carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07803783 | Oct 2026 → Jan 2029 expected | pancreatic ductal adenocarcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07487896 | Mar 2026 → Apr 2028 expected | esophageal squamous cell carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06629597 | Dec 2024 → Dec 2027 expected | nasopharyngeal carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06612151 | Dec 2024 → Dec 2027 expected | small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-13 | Hoffmann-La Roche | Results Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer roche.com ↗
The trial met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001). |
All press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06241846 ↗ |
| Known as | Tam-Peli | “Tambotatug pelitecan (known as Tam-Peli, a new antibody-drug conjugate that targets the immune-checkpoint molecule B7-H3) showed promising clinical efficacy in patients with...” PMID 42734213 ↗ Sep 2026 |
| Known as | tambotatug pelitecan | “Tambotatug pelitecan (known as Tam-Peli, a new antibody-drug conjugate that targets the immune-checkpoint molecule B7-H3) showed promising clinical efficacy in patients with...” PMID 42734213 ↗ Sep 2026 |
| Modality | Other / unclassified | “YL201, a novel B7H3-targeting ADC” PMID 40082695 ↗ Mar 2025 |
| Route | Intravenous | “YL201 intravenous (IV) infusion” NCT05434234 ↗ |
| Target | CD276 | “targets B7-H3 (CD276)” NCT07307053 ↗ |